Alzamend Neuro Stock (NASDAQ:ALZN)
Previous Close
$2.19
52W Range
$1.83 - $40.95
50D Avg
$3.34
200D Avg
$7.20
Market Cap
$1.78M
Avg Vol (3M)
$1.62M
Beta
-0.01
Div Yield
-
ALZN Company Profile
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and AL002 that completed preclinical stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
ALZN Performance
Peer Comparison
| Ticker | Company |
|---|---|
| SNTI | Senti Biosciences, Inc. |
| XFOR | X4 Pharmaceuticals, Inc. |
| VECT | VectivBio Holding AG |
| DAWN | Day One Biopharmaceuticals, Inc. |
| HOOK | HOOKIPA Pharma Inc. |
| ALEC | Alector, Inc. |
| TERN | Terns Pharmaceuticals, Inc. |
| INZY | Inozyme Pharma, Inc. |
| ADVM | Adverum Biotechnologies, Inc. |
| ABOS | Acumen Pharmaceuticals, Inc. |
| SLDB | Solid Biosciences Inc. |
| ADAG | Adagene Inc. |
| MOLN | Molecular Partners AG |
| KZR | Kezar Life Sciences, Inc. |